All Stories

  1. Beyond consensus: Identifying divergences in the care of children with portal hypertension
  2. European Society for Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) position paper on screening, diagnosis and investigation of paediatric metabolic dysfunction‐associated steatotic liver disease
  3. What’s New in Pediatric Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis
  4. ENHANCE: A community partnership charting the evolution of early life CF disease manifestations in a new era of management
  5. Variability in the management of portal hypertension across European countries: A survey‐study by ESPGHAN Portal Hypertension Special Interest Group
  6. Update on pediatric liver transplantation in Europe 2022: An ELITA‐ESPGHAN report
  7. Early postnatal hepatocyte transplantation in a child with molybdenum cofactor deficiency type B
  8. Investigation of an outbreak of novel hepatitis of unknown aetiology in children and adolescents, Ireland, 2021 to 2023
  9. Higher-Dose Infliximab Induction Achieves Better Maintenance Trough Levels in a National Pediatric IBD Cohort—A Retrospective Study
  10. Primary sclerosing cholangitis in children with inflammatory bowel disease: An ESPGHAN position paper from the Hepatology Committee and the IBD Porto group
  11. FISH–Flow Cytometry Reveals Microbiome-Wide Changes in Post-Translational Modification and Altered Microbial Abundance Among Children with Inflammatory Bowel Disease
  12. New guidelines for screening, evaluation and management of hepatobiliary disease in cystic fibrosis
  13. Reply: Development and validation of pFIB scores for exclusion of significant liver fibrosis in pediatric MASLD
  14. Reply: Can pFIB scores reliably exclude significant liver fibrosis in pediatric MASLD?
  15. MRI-serum–based score accurately identifies patients undergoing liver transplant without rejection avoiding the need for liver biopsy: A multisite European study
  16. Development and validation of pFIB scores for exclusion of significant liver fibrosis in pediatric MASLD
  17. Novel Staged Device Occlusion of Portosystemic Shunt With Atrial Flow Regulator in IVC Stent Platform
  18. Paediatric steatotic liver disease has unique characteristics: A multisociety statement endorsing the new nomenclature
  19. ESPGHAN recommendations on treatment of chronic hepatitis C virus infection in adolescents and children including those living in resource‐limited settings
  20. The natural history of cystic fibrosis liver disease a prospective cohort study
  21. Intraperitoneal transplant of Hepatocytes co-Encapsulated with mesenchymal stromal cells in modified alginate microbeads for the treatment of acute Liver failure in Pediatric patients (HELP)—An open-label, single-arm Simon’s two stage phase 1 study pro...
  22. Systemic Complications Secondary to Chronic Liver Disease
  23. Diagnosis of fatty liver in children should occur in parallel to investigation for other causes of liver disease
  24. Adeno-Associated Virus 2 and Human Adenovirus F41 in Wastewater during Outbreak of Severe Acute Hepatitis in Children, Ireland
  25. Fatty liver disease in children (MAFLD/PeFLD Type 2): unique classification considerations and challenges
  26. Advances in medical management of acute liver failure in children: promoting native liver survival
  27. Acute Hepatitis of Unknown Etiology Among Young Children
  28. The impact of liver disease on mortality in cystic fibrosis–A systematic review
  29. Nonalcoholic Fatty Liver Disease
  30. New Horizons in Paediatric Hepatology: A Glimpse of the Future
  31. Nonalcoholic Fatty Liver Disease
  32. Emerging clinical perspectives in cystic fibrosis liver disease
  33. Transient elastography lacks precision in children
  34. Current Practices on Diagnosis, Prevention and Treatment of Post-Transplant Lymphoproliferative Disorder in Pediatric Patients after Solid Organ Transplantation: Results of ERN TransplantChild Healthcare Working Group Survey
  35. NAFLD to MAFLD in adults but the saga continues in children: an opportunity to advocate change
  36. The impact of liver disease on mortality in cystic fibrosis - a systematic review protocol
  37. Clinical management of sickle cell liver disease in children and young adults
  38. Pediatric Focal Lesions in the Liver: A Clinical Perspective
  39. Repeatability of transient elastography in children
  40. Prognostication in Paediatric Acute Liver Failure
  41. Small for Gestational Age Infants: Reading Their Future
  42. Cross-cutting view of current challenges in paediatric solid organ and haematopoietic stem cell transplantation in Europe: the European Reference Network TransplantChild
  43. Alginate microencapsulated human hepatocytes for the treatment of acute liver failure in children
  44. Childhood and Adolescent Nonalcoholic Fatty Liver Disease: Is It Different from Adults?
  45. Improving engraftment of hepatocyte transplantation using alpha-1 antitrypsin as an immune modulator
  46. Understanding susceptibility and targeting treatment in non-alcoholic fatty liver disease in children; moving the fulcrum
  47. Methylcellulose as a scaffold in the culture of liver-organoids for the potential of treating acute liver failure
  48. Transient Elastography Measurements of Spleen Stiffness as a Predictor of Clinically Significant Varices in Children
  49. Immunosuppression Protocol in Liver Transplantation
  50. A New High Throughput Screening Platform for Cell Encapsulation in Alginate Hydrogel Shows Improved Hepatocyte Functions by Mesenchymal Stromal Cells Co-encapsulation
  51. Correction to: Proteomic identification and characterization of hepatic glyoxalase 1 dysregulation in non-alcoholic fatty liver disease
  52. Paediatric fatty liver disease (PeFLD): All is not NAFLD – Pathophysiological insights and approach to management
  53. Vitamin D status and associated genetic polymorphisms in a cohort of UK children with non-alcoholic fatty liver disease
  54. Health Related Quality of Life and Neurocognitive Outcomes in the First Year after Pediatric Acute Liver Failure
  55. Hepatocyte transplantation and advancements in alternative cell sources for liver-based regenerative medicine
  56. Cryopreserved neonatal hepatocytes may be a source for transplantation: Evaluation of functionality toward clinical use
  57. Proteomic identification and characterization of hepatic glyoxalase 1 dysregulation in non-alcoholic fatty liver disease
  58. Human hepatocyte transplantation for liver disease: current status and future perspectives
  59. Fifteen-minute consultation: liver disease in children
  60. Autoimmune Liver Disease in Children with Sickle Cell Disease
  61. Systematic Review
  62. Allograft steatosis in the midst of the epidemic of obesity: Are children in the honeymoon period?
  63. Interim assessment of liver damage in patients with sickle cell disease using new non-invasive techniques
  64. Instant Blood-Mediated Inflammatory Reaction in Hepatocyte Transplantation: Current Status and Future Perspectives
  65. AST-to-platelet ratio index in non-invasive assessment of long-term graft fibrosis following pediatric liver transplantation
  66. Biomarkers in Pediatric Liver Disease
  67. Assessment of Diet and Physical Activity in Paediatric Non-Alcoholic Fatty Liver Disease Patients: A United Kingdom Case Control Study
  68. Bile Acids As Biomarkers - Liver And Gut Cross Talk in NAFLD
  69. Nonalcoholic Fatty Liver Disease
  70. Coculture with Mesenchymal Stem Cells Results in Improved Viability and Function of Human Hepatocytes
  71. Scanning the Scars
  72. Hepatopathy of Mauriac syndrome: a retrospective review from a tertiary liver centre
  73. Noninvasive biomarkers in non-alcoholic fatty liver disease: Current status and a glimpse of the future
  74. Management of Cholestatic Pruritus in Paediatric Patients With Alagille Syndrome
  75. Chronic Acetaminophen Exposure in Pediatric Acute Liver Failure
  76. Transient Elastography Is a Useful Noninvasive Tool for the Evaluation of Fibrosis in Paediatric Chronic Liver Disease
  77. Analysis of adipokine concentrations in paediatric non-alcoholic fatty liver disease
  78. Serum protein N-glycosylation in paediatric non-alcoholic fatty liver disease
  79. Serum Levels of CK18 M30 and Leptin Are Useful Predictors of Steatohepatitis and Fibrosis in Paediatric NAFLD
  80. Predictive Value of Bile Duct Dimensions Measured by Ultrasound in Neonates Presenting With Cholestasis
  81. Fatty liver disease in children: eat now pay later
  82. Human hepatocyte transplantation: state of the art
  83. Crigler–Najjar syndrome: therapeutic options and consequences of mutations in the UGT1A1 complex
  84. The Incidence of Cyclic Vomiting Syndrome in Children: Population-Based Study.
  85. Outcome for children with cyclical vomiting syndrome
  86. A confused child: Answer
  87. A confused child: Question